Sobuzoxane

索布佐生

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameSobuzoxane
Drug Alias NameSobuzoxanum索布佐山SobuzoxanoPerazolinMST-16
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTopoisomerase II inhibitors
TargetsTopoisomerase II
Therapy Area/IndicationsLymphoma, T-CellLymphoma, Non-Hodgkin
Global Approved IndicationsLymphoma, T-CellLymphoma, Non-Hodgkin
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved Date1994/01/01
Country/TerritoryN/A
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesN/A
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesN/A
Active IndicationsLymphoma, T-CellLymphoma, Non-Hodgkin
Inactive IndicationsN/A

Other Information

ATC CodeL01
Related LinksKEGG